BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Herbst DA, Reddy KR. Risk factors for hepatocellular carcinoma. Clin Liver Dis (Hoboken). 2012;1:180-182. [PMID: 31186882 DOI: 10.1002/cld.111] [Cited by in Crossref: 37] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Zhang L, Chen C, Chai D, Li C, Guan Y, Liu L, Kuang T, Deng W, Wang W. The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors. Front Immunol 2022;13:956533. [DOI: 10.3389/fimmu.2022.956533] [Reference Citation Analysis]
2 El Halabi J, LaGuardia L, Walsh RM, Kwon CHD, Menon KVN, Liska D, Burke CA. Hepatocellular carcinoma and solid pseudopapillary neoplasm of the pancreas complicating familial adenomatous polyposis: two cases and review of the literature. Fam Cancer 2022. [PMID: 35896845 DOI: 10.1007/s10689-022-00305-0] [Reference Citation Analysis]
3 Saeed RA, Maqsood M, Saeed RA, Muzammil HS, Khan MI, Asghar L, Nisa SU, Rabail R, Aadil RM. Plant-based foods and hepatocellular carcinoma: A review on mechanistic understanding. Crit Rev Food Sci Nutr 2022;:1-34. [PMID: 35796706 DOI: 10.1080/10408398.2022.2095974] [Reference Citation Analysis]
4 Rallis KS, Makrakis D, Ziogas IA, Tsoulfas G. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World J Clin Oncol 2022; 13(6): 448-472 [DOI: 10.5306/wjco.v13.i6.448] [Reference Citation Analysis]
5 Lee T, Rawding PA, Bu J, Hyun S, Rou W, Jeon H, Kim S, Lee B, Kubiatowicz LJ, Kim D, Hong S, Eun H. Machine-Learning-Based Clinical Biomarker Using Cell-Free DNA for Hepatocellular Carcinoma (HCC). Cancers (Basel) 2022;14:2061. [PMID: 35565192 DOI: 10.3390/cancers14092061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Dat VHX, Nhung BTH, Chau NNB, Cuong PH, Hieu VD, Linh NTM, Quoc NB. Identification of potential microRNA groups for the diagnosis of hepatocellular carcinoma (HCC) using microarray datasets and bioinformatics tools. Heliyon 2022;8:e08987. [PMID: 35243101 DOI: 10.1016/j.heliyon.2022.e08987] [Reference Citation Analysis]
7 Amponsah-Dacosta E. Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030? World J Gastroenterol 2021; 27(36): 6025-6038 [PMID: 34629817 DOI: 10.3748/wjg.v27.i36.6025] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Abd El-Baky RM, Hetta HF, Koneru G, Ammar M, Shafik EA, Mohareb DA, Abbas El-Masry M, Ramadan HK, Abu Rahma MZ, Fawzy MA, Fathy M. Impact of interleukin IL-6 rs-1474347 and IL-10 rs-1800896 genetic polymorphisms on the susceptibility of HCV-infected Egyptian patients to hepatocellular carcinoma. Immunol Res 2020;68:118-25. [PMID: 32504406 DOI: 10.1007/s12026-020-09126-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
9 Li Y, Chen A, Wang H, Han L, Wang R, Zhang G, Yuan Y. Treatment Adherence to Nucleos(t)ide Analogs in Chinese Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: A Single-Center Cross-Sectional Study. Patient Prefer Adherence 2021;15:1729-38. [PMID: 34408406 DOI: 10.2147/PPA.S317250] [Reference Citation Analysis]
10 Vilfranc CL, Che LX, Patra KC, Niu L, Olowokure O, Wang J, Shah SA, Du CY. BIR repeat-containing ubiquitin conjugating enzyme (BRUCE) regulation of β-catenin signaling in the progression of drug-induced hepatic fibrosis and carcinogenesis. World J Hepatol 2021; 13(3): 343-361 [PMID: 33815677 DOI: 10.4254/wjh.v13.i3.343] [Reference Citation Analysis]
11 Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut 2021;70:204-14. [PMID: 32747413 DOI: 10.1136/gutjnl-2020-321702] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 62.0] [Reference Citation Analysis]
12 Abd El Aziz MA, Facciorusso A, Nayfeh T, Saadi S, Elnaggar M, Cotsoglou C, Sacco R. Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. Vaccines (Basel) 2020;8:E616. [PMID: 33086471 DOI: 10.3390/vaccines8040616] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
13 Deepak P, Siddalingam R, Kumar P, Anand S, Thakur S, Jagdish B, Jaiswal S. Gene based nanocarrier delivery for the treatment of hepatocellular carcinoma. Journal of Drug Delivery Science and Technology 2020;59:101837. [DOI: 10.1016/j.jddst.2020.101837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Gomaa SH, Abaza MM, Elattar HA, Amin GA, Elshahawy DM. Soluble cluster of differentiation 26/soluble dipeptidyl peptidase-4 and glypican-3 are promising serum biomarkers for the early detection of Hepatitis C virus related hepatocellular carcinoma in Egyptians. Arab J Gastroenterol 2020;21:224-32. [PMID: 32891543 DOI: 10.1016/j.ajg.2020.04.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Alghamdi IG, Alghamdi MS. The Incidence Rate of Liver Cancer in Saudi Arabia: An Observational Descriptive Epidemiological Analysis of Data from the Saudi Cancer Registry (2004-2014). Cancer Manag Res 2020;12:1101-11. [PMID: 32104090 DOI: 10.2147/CMAR.S232600] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Elgamal S, Ghafar AA, Ghoneem E, Elshaer M, Alrefai H, Elemshaty W. Characterization of patients with hepatocellular carcinoma on the way for early detection: one center experience. Egypt J Intern Med 2018;30:231-8. [DOI: 10.4103/ejim.ejim_29_18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Trad D, Bibani N, Sabbah M, Elloumi H, Gargouri D, Ouakaa A, Kharrat J. Known, new and emerging risk factors of hepatocellular carcinoma (review). La Presse Médicale 2017;46:1000-7. [DOI: 10.1016/j.lpm.2017.09.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
18 Sghaier I, Mouelhi L, Rabia NA, Alsaleh BR, Ghazoueni E, Almawi WY, Loueslati BY. Genetic variants in IL-6 and IL-10 genes and susceptibility to hepatocellular carcinoma in HCV infected patients. Cytokine. 2017;89:62-67. [PMID: 28340949 DOI: 10.1016/j.cyto.2016.10.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
19 Zhang YQ, Guo JS. Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2015; 21(13): 3860-3866 [PMID: 25852270 DOI: 10.3748/wjg.v21.i13.3860] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
20 Ahmed HH, Shousha WG, Shalby AB, El-mezayen HA, Ismaiel NN, Mahmoud NS. Curcumin: a unique antioxidant offers a multimechanistic approach for management of hepatocellular carcinoma in rat model. Tumor Biol 2015;36:1667-78. [DOI: 10.1007/s13277-014-2767-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
21 Marrero J, Maluccio MA, McCurdy H, Abou-Alfa GK. Expert perspectives on evidence-based treatment planning for patients with hepatocellular carcinoma. Cancer Control 2014;21:5-16. [PMID: 24681845 DOI: 10.1177/1073274814021002s02] [Reference Citation Analysis]